ABUS vs REPL vs ASMB vs HBIO vs VKTX

For growth investors, Assembly Biosciences, Inc.

(ASMB) is the stronger pick with 153. 5% revenue growth year-over-year, versus -8. 1% for Harvard Bioscience, Inc. (HBIO). Analysts rate Arbutus Biopharma Corporation (ABUS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Viking Therapeutics, Inc.

(VKTX) delivered a total return of +435. 3%, compared to -90. 7% for Harvard Bioscience, Inc. (HBIO). Over 10 years, the gap is even starker: VKTX returned +25. 8% versus REPL's -78. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Replimune Group, Inc.

(REPL) is the lower-risk stock at 0. 83β versus Harvard Bioscience, Inc. 's 2. 03β — meaning HBIO is approximately 144% more volatile than REPL relative to the S&P 500. On balance sheet safety, Viking Therapeutics, Inc. (VKTX) carries a lower debt/equity ratio of 0% versus 3% for Harvard Bioscience, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Assembly Biosciences, Inc.

(ASMB) is pulling ahead at 153. 5% versus -8. 1% for Harvard Bioscience, Inc. (HBIO). On earnings-per-share growth, the picture is similar: Assembly Biosciences, Inc. grew EPS 91. 8% year-over-year, compared to -357. 1% for Harvard Bioscience, Inc.. Over a 3-year CAGR, HBIO leads at -8. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Replimune Group, Inc.

(REPL) is the more profitable company, earning 0. 0% net margin versus -237. 9% for Arbutus Biopharma Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REPL leads at 0. 0% versus -271. 0% for ABUS. At the gross margin level — before operating expenses — ASMB leads at 99. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Replimune Group, Inc.

(REPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83)). Harvard Bioscience, Inc. (HBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REPL: -78. 0%, HBIO: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ABUS is a small-cap high-growth stock; REPL is a small-cap quality compounder stock; ASMB is a small-cap high-growth stock; HBIO is a small-cap quality compounder stock; VKTX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.